The International Myeloma Foundation: Newly Published Study Says Patients Identified with High-Risk Presymptomatic Myeloma May Benefit From Early Intervention

Published: Aug 01, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NORTH HOLLYWOOD, Calif.--(BUSINESS WIRE)--The International Myeloma Foundation (IMF) – improving the quality of life of myeloma patients while working toward prevention and a cure – today said a study just published in a major medical journal could change the way certain patients with early myeloma are treated. The standard of care for patients with smoldering myeloma – myeloma diagnosed so early there are no symptoms – is to wait and watch until symptoms occur. But a study just published in the New England Journal of Medicine concluded that early intervention and maintenance with a REVLIMID®-based regimen in patients with high-risk smoldering multiple myeloma “significantly delayed the time to progression to symptomatic disease, and resulted in an overall survival benefit.”

Help employers find you! Check out all the jobs and post your resume.

Back to news